1[1]Dvorak HF, Broun LF,Detmar M et al.Vascular permeabiliby factor/vascular endothelial growth factor, microvascular hyper-permeability and angiogenesis [J]. Am J Pathol,1995；146:1029.
2[2]Weidner N. Curred pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors [J]. Breast Cancer Res Treat,1995；36:169～180.
3[3]Cao YH, O'Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produce long-term dormancy of metastasis [J]. Jclin I NVRST,1998；101:1055.
5[5]Tanigawa N, Amaya H, Matsumura M, et al. Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas [J]. Cancer Res,1996；56:2671.
6[6]Takahama M, Tsutsumi M, Tsujiuchi T,et al. Frequent expression of the vascular endothelial growth factor in human non-small-cell lung cancers [J]. Jpn J Clin Oncol,1998；28(3):176～181.
7[7]Noel W, Peter RC, Jonathan F, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma [J]. AM J Pathol,1993；142(2):40.
8[8]Walkui S, Furusato M, Itoh T, et al. Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis :a morphometric study [J]. J Pathol,1992；168:257～262.
9[9]Berger DP, Herbstritt L, Dengler WA, et al. Vascular endothelial growth factor (VEGF) mRNA expression in human models of different histologies [J]. Ann Oncol,1995；6:818～825.
10[10]Harris AL, Zhang H, Moghaddam, et al. Breast cancer angiogenesis new approaches to therapy via antiangiogenesis, hypoxic, activated drugs and vascular targeting [J]. Breast Cancer Res Treat,1996；38:97～108.
